Transplanted fetal striatum in Huntington's disease: Phenotypic development and lack of pathology
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Neural and stem cell transplantation is emerging as a potential treatment for neurodegenerative diseases. Transplantation of specific committed neuroblasts (fetal neurons) to the adult brain provides such scientific exploration of these new potential therapies. Huntington's disease (HD) is a fatal, incurable autosomal dominant (CAG repeat expansion of huntingtin protein) neurodegenerative disorder with primary neuronal pathology within the caudate–putamen (striatum). In a clinical trial of human fetal striatal tissue transplantation, one patient died 18 months after transplantation from cardiovascular disease, and postmortem histological analysis demonstrated surviving transplanted cells with typical morphology of the developing striatum. Selective markers of both striatal projection and interneurons such as dopamine and c-AMP-related phosphoprotein, calretinin, acetylcholinesterase, choline acetyltransferase, tyrosine hydroxylase, calbindin, enkephalin, and substance P showed positive transplant regions clearly innervated by host tyrosine hydroxylase fibers. There was no histological evidence of immune rejection including microglia and macrophages. Notably, neuronal protein aggregates of mutated huntingtin, which is typical HD neuropathology, were not found within the transplanted fetal tissue. Thus, although there is a genetically predetermined process causing neuronal death within the HD striatum, implanted fetal neural cells lacking the mutant HD gene may be able to replace damaged host neurons and reconstitute damaged neuronal connections. This study demonstrates that grafts derived from human fetal striatal tissue can survive, develop, and are unaffected by the disease process, at least for 18 months, after transplantation into a patient with HD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain
DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P., & Aronin, N. (1997) · Science · doi:10.1126/science.277.5334.1990 · Cited by 2,439
Neuropathological Classification of Huntingtonʼs Disease
VONSATTEL, J.-P., MYERS, R. H., STEVENS, T. J., FERRANTE, R. J., BIRD, E. D., & RICHARDSON, E. P. (1985) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198511000-00003 · Cited by 2,227
Striatal interneurones: chemical, physiological and morphological characterization
Kawaguchi, Y., Wilson, C. J., Augood, S. J., & Emson, P. C. (1995) · Trends in Neurosciences · doi:10.1016/0166-2236(95)98374-8 · Cited by 1,198
Nuclear and Neuropil Aggregates in Huntington’s Disease: Relationship to Neuropathology
Gutekunst, C.-A., Li, S.-H., Yi, H., Mulroy, J. S., Kuemmerle, S., Jones, R., Rye, D., Ferrante, R. J., Hersch, S. M., & Li, X.-J. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-07-02522.1999 · Cited by 914
Self-citationKordower, J. H., Freeman, T. B., Snow, B. J., Vingerhoets, F. J. G., Mufson, E. J., Sanberg, P. R., Hauser, R. A., Smith, D. A., Nauert, G. M., Perl, D. P., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504273321702 · Cited by 860
Self-citationDopamine release from nigral transplants visualized in vivo in a Parkinson's patient
Piccini, P., Brooks, D. J., Björklund, A., Gunn, R. N., Grasby, P. M., Rimoldi, O., Brundin, P., Hagell, P., Rehncrona, S., Widner, H., et al. (1999) · Nature Neuroscience · doi:10.1038/16060 · Cited by 700
Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease
Freeman, T. B., Olanow, C. W., Hauser, R. A., Nauert, G. M., Smith, D. A., Borlongan, C. V., Sanberg, P. R., Holt, D. A., Kordower, J. H., Vingerhoets, F. J. G., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380307 · Cited by 403
Self-citationFerrante, R., Kowall, N., & Richardson, E. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-12-03877.1991 · Cited by 306
Isacson, O., Brundin, P., Kelly, P. A. T., Gage, F. H., & Björklund, A. (1984) · Nature · doi:10.1038/311458a0 · Cited by 299
Self-citation
Cited by
Stem cell therapy for human neurodegenerative disorders–how to make it work
Lindvall, O., Kokaia, Z., & Martinez-Serrano, A. (2004) · Nature Medicine · doi:10.1038/nm1064 · Cited by 915
Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities
Tabrizi, S. J., Flower, M. D., Ross, C. A., & Wild, E. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0389-4 · Cited by 538
Stem cell‐based cell therapy in neurological diseases: A review
Kim, S. U., & de Vellis, J. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.22054 · Cited by 426
Huntington's disease: from pathology and genetics to potential therapies
Imarisio, S., Carmichael, J., Korolchuk, V., Chen, C.-W., Saiki, S., Rose, C., Krishna, G., Davies, J. E., Ttofi, E., Underwood, B. R., et al. (2008) · Biochemical Journal · doi:10.1042/bj20071619 · Cited by 409
Bachoud-Lévi, A.-C., Gaura, V., Brugières, P., Lefaucheur, J.-P., Boissé, M.-F., Maison, P., Baudic, S., Ribeiro, M.-J., Bourdet, C., Remy, P., et al. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70381-7 · Cited by 358
Guzman, R., Uchida, N., Bliss, T. M., He, D., Christopherson, K. K., Stellwagen, D., Capela, A., Greve, J., Malenka, R. C., Moseley, M. E., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608519104 · Cited by 331
Neural stem cell therapy for neurological diseases: dreams and reality
Rossi, F., & Cattaneo, E. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn809 · Cited by 298
Aubry, L., Bugi, A., Lefort, N., Rousseau, F., Peschanski, M., & Perrier, A. L. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808488105 · Cited by 291
Pollock, K., Stroemer, P., Patel, S., Stevanato, L., Hope, A., Miljan, E., Dong, Z., Hodges, H., Price, J., & Sinden, J. D. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2005.12.011 · Cited by 277
Mutant huntingtin is present in neuronal grafts in huntington disease patients
Cicchetti, F., Lacroix, S., Cisbani, G., Vallières, N., Saint‐Pierre, M., St‐Amour, I., Tolouei, R., Skepper, J. N., Hauser, R. A., Mantovani, D., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24174 · Cited by 193
“To date, these transplants have generally produced transient or no clinical benefits despite evidence that they survive in the short-term.(11) This failure of clinical response to such targeted grafts may relate to the widespread pathology now recognized in HD from an early disease stage, but may also relate to the fi…”
BackgroundMethodResultInfluentialSelf-citationClinical Potential of Minocycline for Neurodegenerative Disorders
BLUM, D., CHTARTO, A., TENENBAUM, L., BROTCHI, J., & LEVIVIER, M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.07.012 · Cited by 157
“, 2002) and that their clinical potential have to be further assessed in a more important cohort of patients, fetal tissue survives well, reconstitutes connections and can provide significant motor, cognitive and functional recovery up to 2 years after transplantation in some HD patients (Bachoud-Levi et al., 2000; Fr…”
BackgroundNeural progenitor NT2N cell lines from teratocarcinoma for transplantation therapy in stroke
HARA, K., YASUHARA, T., MAKI, M., MATSUKAWA, N., MASUDA, T., YU, S., ALI, M., YU, G., XU, L., & KIM, S. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.04.005 · Cited by 85
Metadata
- Authors
- Freeman, T. B., Cicchetti, F., Hauser, R. A., Deacon, T. W., Li, X.-J., Hersch, S. M., Nauert, G. M., Sanberg, P. R., Kordower, J. H., Saporta, S., & Isacson, O.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2000-12-05
- Volume
- 97
- Issue
- 25
- Pages
- 13877-13882
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2101326888
- Cited by
- 267
- References
- 42
- FWCI
- 4.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.